Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A. Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
| Date | Status | Outer | Rating | Price |
|---|---|---|---|---|
| Jul-31-26 | Downgrade | Robert W. Baird | Outperform → Neutral | $3 |
| Jul-31-26 | Downgrade | H.C. Wainwright | Buy → Neutral | $3 |
| Mar-10-26 | Initiated | Rodman & Renshaw | Buy | $28 |
| Feb-05-26 | Initiated | Cantor Fitzgerald | Overweight | |
| Oct-13-25 | Upgrade | H.C. Wainwright | Neutral → Buy | $15 |
| Jul-16-25 | Downgrade | H.C. Wainwright | Buy → Neutral | |
| Jul-11-25 | Resumed | H.C. Wainwright | Buy | $27 |
| Jan-19-23 | Initiated | Piper Sandler | Overweight | $8 |
| Nov-04-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform | $7 → $10 |
| Feb-09-22 | Upgrade | JP Morgan | Underweight → Neutral | $8 |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight | $27 → $10 |
| Aug-06-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform | $6 |
| Aug-06-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform | $17 → $8 |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral | |
| Jul-02-20 | Initiated | Morgan Stanley | Overweight | $34 |
| Mar-04-20 | Initiated | Barclays | Overweight | $30 |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral | |
| Jul-23-19 | Upgrade | JP Morgan | Neutral → Overweight | $8 → $16 |
| Jul-05-19 | Reiterated | Robert W. Baird | Outperform | $15 → $25 |
| Jul-05-19 | Reiterated | H.C. Wainwright | Buy | $29 → $32 |